In the last quarter of 2016, FierceBiotech included Oncorus on its Fierce 15 list of the year’s most promising biotech firms. FierceBiotech recognized the promise of Oncorus’ unique approach to immuno-oncology while honoring the organization’s commitment to making the therapy accessible. According to Mitchell Finer, one of the founders of Oncorus, the oncolytic virus being engineered by the firm can be manufactured at large scale and able to be shipped around the world.
Currently, next-generation cancer treatments are limited to the American and European markets due in part to the expensive manufacturing methods that are employed. Offering the oncolytic virus globally could prove a game changer for markets across the world as a supplement to traditional treatment modalities, including radiation and chemotherapy.
Finer also envisions multiple oncolytic virus products becoming available over the course of the next decade. Understanding that one size does not fit all for cancer treatment will allow Oncorus to engineer a range of treatments designed to target different solid tumors. By following the regulatory pathway of Imlygic, an oncolytic virus that already received approval from the FDA, Oncorus aims to see its first therapy, ONCR-001, gain approval and become available to patients as soon as possible.
Oncorus is an immuno-oncology company based in Cambridge, Massachusetts. The company was launched in 2016 by MPM Capital with the launch team of Mitchell Finer, PhD as Chief Executive Officer and Thomas Chalberg, PhD MBA as Chief Operating Officer.
